NeuroStar

NeuroStar uses transcranial magnetic stimulation (TMS) to target key areas of the brain that are underactive in people with depression. It is different from ECT (electroconvulsive therapy). Although the exact cause of depression is unknown, patients with depression tend to have an imbalance of activity levels in certain parts of the brain. NeuroStar TMS helps depression by helping to restore this balance.

Call Desert View Counseling & Consulting to inquire about your suitability for NeuroStar TMS, or book an appointment online today or call/text us at 623-487-7763

What is NeuroStar Advanced Therapy (TMS)?

During a NeuroStar treatment session, a magnet similar to an MRI machine is used to stimulate nerve cells in an area of the brain that is involved in controlling mood. These magnetic pulses may have a positive effect on the brain’s neurotransmitter levels. This makes long-term remission possible.

Treatment with NeuroStar Advanced Therapy generally consists of the following:

• Therapy sessions conducted in your NeuroStar psychiatrist’s office
• A quick return to your normal routine
• Treatments conducted while you are awake
• NeuroStar Advanced Therapy does not usually cause problems with memory or sleep and has no sexual side effects
• Coverage from most insurance plans, including Medicare and TRICARE.

This innovative treatment has been tested and proven effective over 5 million treatment sessions. TMS treatment is bringing new hope to people suffering from depression and mental illness every day.

What to Expect

Here’s what you can expect from a NeuroStar Advanced Therapy (TMS) session:

Before Treatment

Treatment is conducted while the patient is reclining in a chair. A small magnetic coil will be positioned lightly against the head.

During Treatment

NeuroStar delivers magnetic stimulation directly to the target area of the brain. There will be a clicking sound and a tapping sensation on the head. Depending on doctor recommendations, each treatment typically lasts less than 20 minutes, and sometimes as little as 3 ½ minutes. Treatments are administered 5 days a week for approximately 4-6 weeks*. It is important that you miss as few of these appointments as possible in order to maximize the benefit of the treatment.

After Treatment

NeuroStar Advanced Therapy: Depending on your doctor’s recommendation, each treatment takes between 3 and 19 minutes.

NeuroStar Advanced Therapy System

The NeuroStar Advanced Therapy System is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode.

The NeuroStar Advanced Therapy system is intended to be used as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).

The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of TMS therapy (<0.1% per patient).

NeuroStar Advanced Therapy is only available by prescription.

Visit neurostar.com for full safety and prescribing information.

TMS Clinical Trials & Academic Studies

1. Janicak PG, et al. (2015). Transcranial Magnetic Stimulation for The Treatment Of Major Depression. Neuropsychiatry Dis Treat 2015;11:1549–1560. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492646/
2. O’Reardon JP, et al. (2007). Efficacy and safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial. Biol Psychiatry, 62(11):1208-1216. https://www.ncbi.nlm.nih.gov/pubmed/17573044
3. George MS, et al. (2010). Daily Left Prefrontal Transcranial Magnetic Stimulation Therapy for Major Depressive Disorder: A Sham-Controlled Randomized Trial. Arch Gen Psychiatry, 67(5):507-516. https://www.ncbi.nlm.nih.gov/pubmed/20439832